Diagnostic and treatment of chronic pathologies such as Lyme disease
AssigneesCentre National De La Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale
InventorsHugues Gascan, Marc Michaël Bransten, Sylvie Chevalier, Hans Yssel
Life of this patent
Estimating the term…
Abstract
The present invention relates to several biomarkers, including IL-1RA, IFN-γ and GM-CSF, whose expressions at the mRNA level and at the protein level, correlate with chronic pathologies, such as Lyme disease, in particular the late chronic form of Lyme disease. More specifically, the invention provides methods and kits for the diagnosis of such chronic pathologies and for the assessment of a patient's response to a treatment, as well as methods and therapeutic agents for the treatment of such chronic pathologies.
Claims5
A method for treating a late chronic form of Lyme disease in a subject, said method comprising steps of:
- (A) verifying that the subject has a late chronic form of Lyme disease;
- and
- (B) administering, to the subject, a treatment for late chronic form of Lyme disease comprising a therapeutically effective amount of an IL-RA therapeutic agent selected from the group consisting of IL-1α, IL-1β, anti-IL-1RA antibodies, and anti-IL-1RA interfering agents, wherein verifying that the subject has a late chronic form of Lyme disease comprises steps of:
- (a) determining, in a biological sample obtained from said subject, an expression level of IL-1RA and an expression level of IFN-γ;
- and
- (b) calculating a ratio [IL-1RA]/[IFN-γ] between the expression level of IL-1RA and the expression level of IFN- determined in step (a);
- and
- (c) comparing the ratio [IL-1RA]/[IFN-γ] calculated in step (b) with a ratio [IL-1RA]/[IFN-γ] determined using a biological sample obtained from a healthy subject or with a predetermined threshold ratio [IL-1RA]/[IFN-γ]0, wherein the healthy subject does not have a pathology or an infection,
- wherein the ratio [IL-1RA]/[IFN-γ] calculated in step (b) that is higher than the ratio [IL-1RA]/[IFN-γ] determined for the healthy subject, or that is higher than the predetermined threshold ratio [IL-1RA]/[IFN-γ]0, is indicative of the late chronic chronic form of Lyme disease;
- and/or comprises steps of:
- (a′) determining, in a biological sample obtained from said subject, an expression level of IL-1RA and an expression level GM-CSF;
- (b′) calculating a ratio [IL-1RA]/[GM-CSF] between the expression level of IL-1RA and the expression level of GM-CSF determined in step (a′);
- and
- (c′) comparing the ratio [IL-1RA]/[GM-CSF] calculated in step (b′) with a ratio [IL-1RA]/[GM-CSF] determined using a biological sample obtained from a healthy subject or with a predetermined threshold [IL-1RA]/[GM-CSF]0, wherein the healthy subject does not have a pathology or an infection,
- wherein the ratio [IL-1RA]/[GM-CSF] calculated in step (b′) that is higher than the ratio [IL-1RA]/[GM-CSF] determined for a healthy subject, or that is higher than the predetermined threshold ratio [IL-1RA]/[GM-CSF]0, is indicative of the late chronic form of Lyme disease.
Dependencies are inferred from the claim text.